Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive [7]

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 207-209

  Grice, G R ^a,b   Milligan, P E ^b   Eby, C ^b   Gage, Brian F ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CITALOPRAM; CYTOCHROME P450 2C9; DILTIAZEM; DNA; FOLIC ACID; HEPARIN; LISINOPRIL; MENADIONE EPOXIDE; PRAVASTATIN; THIAMINE; TRIHEXYPHENIDYL; WARFARIN;

AGED; ALCOHOLISM; BLEEDING DISORDER; CASE REPORT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; DEPRESSION; DNA ISOLATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; GENE FREQUENCY; GENOTYPE; HEART ATRIUM FIBRILLATION; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFORMED CONSENT; LETTER; MALE; NEUROLOGIC DISEASE; OPEN STUDY; PARKINSON DISEASE; PATIENT REFERRAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIXED FUNCTION OXYGENASES; OVERDOSE; PHARMACOGENETICS; STEROID HYDROXYLASES; WARFARIN;

EID: 37549064732     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02797.x     Document Type: Letter

References (13)

1. Millican E, Lenzini P, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Chloisy JC, Barrack R, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage B. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 2007; 110: 1511-5.
2. Fukuda T, Tanabe T, Ohno M, Tougou K, Fujio Y, Azuma J, Yamamoto I, Takeda A. Warfarin dose requirement for patients with both VKORC1 3673A/ A and CYP2C9*3/*3 genotypes. Clin Pharmacol Ther 2006; 80: 553-4.
3. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Peterson P. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-92.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
5. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-9.
6. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205-10.
7. Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics 2005; 6: 503-13.
8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AL. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
9. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000; 133: 687-95.
10. Ezekowitz MD, James KE, Radford MJ, Rickles FR, Redmond N. Initiating and maintaining patients on warfarin anticoagulation: The importance of monitoring. J Cardiovasc Pharmacol Ther 1999; 4: 3-8.
11. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000; 29: 31-4.
12. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahe I, Donval V, Seux ML, Romain-Pilotaz M, Gisselbrecht M, Verney M, Pautas E. Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. Am J Med 2005; 118: 137-42.
13. Lenzini P, Grice G, Milligan P, Gatchel S, Deych E, Eby C, Burnett RS, Clohisy J, Barrack R, Gage B. Optimal dose adjustment in orthopaedic patients beginning warfarin therapy. Ann Pharmacother 2007; 41: 1798-804.